The ERECTA gene regulates plant transpiration efficiency in Arabidopsis

Assimilation of carbon by plants incurs water costs. In the many parts of the world where water is in short supply, plant transpiration efficiency, the ratio of carbon fixation to water loss, is critical to plant survival, crop yield and vegetation dynamics. When challenged by variations in their environment, plants often seem to coordinate photosynthesis and transpiration, but significant genetic variation in transpiration efficiency has been identified both between and within species. This has allowed plant breeders to develop effective selection programmes for the improved transpiration efficiency of crops, after it was demonstrated that carbon isotopic discrimination, Delta, of plant matter was a reliable and sensitive marker negatively related to variation in transpiration efficiency. However, little is known of the genetic controls of transpiration efficiency. Here we report the isolation of a gene that regulates transpiration efficiency, ERECTA. We show that ERECTA, a putative leucine-rich repeat receptor-like kinase (LRR-RLK) known for its effects on inflorescence development, is a major contributor to a locus for Delta on Arabidopsis chromosome 2. Mechanisms include, but are not limited to, effects on stomatal density, epidermal cell expansion, mesophyll cell proliferation and cell-cell contact.     

Timing of the steps in transformation of C3H 10T 1/2 cells by X-irradiation

Transformation of cells in culture by chemical carcinogens or X rays seems to require at least two steps. The initial step is a frequent event; for example, after transient exposure to either methylcholanthrene or X rays, almost every cell of established lines of mouse embryo fibroblasts proved capable of yielding transformed, tumorigenic descendants. Although results were interpreted as indicating that 100% of the progeny of methylcholanthrene-treated cells were potentially transformed, later experiments showed that only a very small minority of the progeny of cells initiated by X rays or methylcholanthrene actually produced transformed colonies. We thus concluded that there must be a second step in transformation that is a very rare event. We assumed that this event occurred after the cultures became confluent, a time when transformed cells have a selective growth advantage. Since then, however, others have shown that transformation can occur soon after initiation and that clones of transformed cells may already be present by the time initiated cultures become confluent. It has been hypothesized that the second step behaves like a spontaneous mutation in having a constant but small probability of occurring each time an initiated cell divides. We show here that the clone size distribution of transformed cells in growing cultures initiated by X rays is, indeed, exactly what would be expected on that hypothesis.     

The South African One Thousand Schools Project and Stephens' Quality Wheel

This paper describes the development of a qualitative educational initiative in South Africa: the One Thousand Schools Project. This multiagency initiative is headed by the Independent Development Trust (IDT), a nongovernmental organization. The project soon experienced issues of complexity, however, due to, first, the number of partners involved and, second, the scope of the project: qualitative educational improvement within 1000 schools that were discriminated against under the historical segregated educational system. Seeking an approach to guide the project the IDT opted for Stephens' Quality Wheel, an educational model whose objective is to achieve systemic improvement via coordinating three key educational elements: the agents; conditions for improvement; and a guiding set of educational goals and principles. This paper considers the project's use of Stephens' model, highlighting the insights gained by the project, but also the limited nature of its systemicity. Finally, an inherent tension which was experienced in the project and thereby identified in the model is debated.     

Patterns of somatic mutation in human cancer genomes

Cancers arise owing to mutations in a subset of genes that confer growth advantage. The availability of the human genome sequence led us to propose that systematic resequencing of cancer genomes for mutations would lead to the discovery of many additional cancer genes. Here we report more than 1,000 somatic mutations found in 274 megabases (Mb) of DNA corresponding to the coding exons of 518 protein kinase genes in 210 diverse human cancers. There was substantial variation in the number and pattern of mutations in individual cancers reflecting different exposures, DNA repair defects and cellular origins. Most somatic mutations are likely to be 'passengers' that do not contribute to oncogenesis. However, there was evidence for 'driver' mutations contributing to the development of the cancers studied in approximately 120 genes. Systematic sequencing of cancer genomes therefore reveals the evolutionary diversity of cancers and implicates a larger repertoire of cancer genes than previously anticipated.     

SV40 association with human malignancies and mechanisms of tumor immunity by large tumor antigen

SV40 was discovered as a contaminate of poliovirus vaccine lots distributed to millions of individuals in the United States between 1955 and 1963 while contaminated vaccine batches were later circulated worldwide. After SV40 was observed to cause in vitro animal and human cell transformations and in vivo tumor formations in animals, the search for a connection between the virus and human malignancies has continued to the present day. Different molecular methods have been used to detect SV40 gene products in a variety of human cancers, though SV40 causality in these tumor types has yet to be established. These data, however, are not without controversial issues related to inconclusive SV40 serological and epidemiological evidence alongside tools and methodologies that may contribute to false-positive results in human specimens. This review will also explore how vaccination against SV40 protein products may be used to help prevent and treat individuals with SV40-expressing cancers. Received 19 September 2006; received after revision 8 November 2006; accepted 13 December 2006